Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization

Annals of Surgical Oncology

Volumn 19, Issue 11, 2012, Pages 3540-3546

  Wang, Yan ^a   Chen, Yi ^a   Ge, Ningling ^a   Zhang, Lan ^a   Xie, Xiaoying ^a   Zhang, Jubo ^a   Chen, Rongxin ^a   Wang, Yanhong ^a   Zhang, Boheng ^a   Xia, Jinglin ^a   Gan, Yuhong ^a   Ren, Zhenggang ^a   Ye, Shenglong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; CISPLATIN; FLUOROURACIL; GAMMA GLUTAMYLTRANSFERASE; IODINATED POPPYSEED OIL; MITOMYCIN;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CHEMOEMBOLIZATION; CHILD; DATA BASE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL RATE; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CISPLATIN; ETHIODIZED OIL; FEMALE; FLUOROURACIL; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MITOMYCIN; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84868194711     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2368-5     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108. (Pubitemid 40372904)
2. Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 2010;7:448-58.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-36. (Pubitemid 43112690)
4. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet. 2002;359:1734-9. (Pubitemid 34607087)
5. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164-71. (Pubitemid 34454013)
6. Amarapurkar D, Han KH, Chan HL, Ueno Y. Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific region. J Gastroenterol Hepatol. 2009;24:955-61.
7. Debruyne EN, Delanghe Jr. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: New aspects and applications. Clin Chim Acta. 2008;395:19-26.
8. Yamamoto K, Imamura H, Matsuyama Y, et al. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol. 2009;16:2795-804.
9. Chan SL, Mo FK, Johnson PJ, et al. New utility of an old marker: Serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol. 2009;27: 446-52.
10. Riaz A, Ryu RK, Kulik LM, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: Oncologic marker of radiologic response, progression, and survival. J Clin Oncol. 2009;27:5734-42.
11. Shao YY, Lin ZZ, Hsu C, et al. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer. 2010; 116:4590-6.
12. Toyoda H, Kumada T, Kaneoka Y, et al. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol. 2008;49:223-32.
13. Toyoda H, Kumada T, Kiriyama S, et al. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2006;4:111-7. (Pubitemid 43129532)
14. Toyoda H, Kumada T, Osaki Y, et al. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol. 2006;4:1528-36. (Pubitemid 44895414)
15. Pompili M, Rapaccini GL, Covino M, et al. Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy. Cancer. 2001;92:126-35. (Pubitemid 32623049)
16. Farinati F, Marino D, De Giorgio M, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: Both or neither? Am J Gastroenterol. 2006;101:524-32. (Pubitemid 43340928)
17. Kohles N, Nagel D, Jüngst D, et al. Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients. BMC Cancer. 2011;11:202.
18. Mailey B, Artinyan A, Khalili J, et al. Evaluation of absolute serum a-fetoprotein levels in liver transplant for hepatocellular cancer. Arch Surg. 2011;146:26-33.
19. Tsai YJ, Hsu CY, Huang YH, et al. Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma. Hepatol Int. 2011;5:975-84.
20. Kohles N, Nagel D, Jüngst D, et al. Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. Tumour Biol. 2012; 33:33-40.
21. Mitsuhashi N, Kobayashi S, Doki T, et al. Clinical significance of alpha-fetoprotein: Involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23:e189-97. (Pubitemid 352019435)
22. Yang X, Zhang Y, Zhang L, Mao J. Silencing alpha-fetoprotein expression induces growth arrest and apoptosis in human hepatocellular cancer cell. Cancer Lett. 2008;271:281-93.
23. Li M, Zhou S, Liu X, et al. Alpha-Fetoprotein shields hepatocellular carcinoma cells from apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand. Cancer Lett. 2007;249:227-34. (Pubitemid 46452932)
24. Fujiyama S, Tanaka M, Maeda S, et al. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology. 2002;62(Suppl 1):57-63. (Pubitemid 34702021)
25. Huo TI, Hsu CY, Huang YH, et al. Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy. BMC Gastroenterol. 2010;10:146.